General Approach to Evaluating the Utility of Genetic Panels. Policy Specific Section: Medical Necessity and Investigational / Experimental

Transcription

1 Medical Policy General Approach to Evaluating the Utility of Genetic Panels Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: September 27, 2013 January 30, 2015 Definitions of Decision Determinations Medically Necessary: A treatment, procedure or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition. Investigational/Experimental: A treatment, procedure or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted. Split Evaluation: Blue Shield of California / Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a Split Evaluation, where a treatment, procedure or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances. Description There are an increasing number of commercially available genetic panels, coinciding with the evolution of genetic testing that allows simultaneous analysis of multiple genes. This includes panels performed by next generation sequencing, massive parallel sequencing, and panels performed by microarray testing. Panel testing offers potential advantages, as well as pitfalls,

2 compared to direct sequence analysis. This concept policy outlines a framework for evaluating the utility of genetic panels, by classifying panels into clinically relevant categories and developing criteria that can be used for evaluating panels in each category. Policy Genetic panels that use next generation sequencing or chromosomal microarray, and are classified in one of the categories below, may be considered medically necessary when all criteria are met for each category, as outlined in the Rationale Section: Panels for hereditary or genetic conditions ο Diagnosis of heritable conditions ο Risk assessment for asymptomatic individuals Cancer panels ο Risk assessment for asymptomatic individuals ο Targeted treatment based on mutation analysis Reproductive panels ο Preconception testing of at-risk individuals ο Preconception screening ο Prenatal testing Genetic panels that use next generation sequencing or chromosomal microarray that do not meet the criteria for a specific category are considered investigational. Policy Guideline If a specific analyte is listed in codes or , that CPT code would be reported along with the unlisted code (1 unit) for any analytes on the panel that are not listed in the CPT codes. If none of the analytes on the panel are listed in the more specific CPT codes, unlisted code would be reported for the whole test. If the panel utilizes an algorithmic analysis of the results of the component tests to produce a numeric score or probability, it would be a multianalyte assay with algorithm analysis (MAAA) and reported with one of the specific codes in the 815XX section or appendix O in CPT. If there is no specific code listed, the unlisted MAAA code would be used. Internal Information There is an MD Determination Form for this Medical Policy. It can be found on the following Web page: 2 of 28

3 Documentation Required for Clinical Review Physician order for genetic test Name and description of genetic panel Name of laboratory that performed the test Any available evidence supporting the analytic validity and clinical validity/utility of the specific genetic panel CPT codes billed for the particular genetic panel History and physical and/or consultation notes including: ο Family history if applicable ο How test result will impact clinical decision making ο Reason for performing test ο Signs/symptoms/test results related to reason for genetic testing The materials provided to you are guidelines used by this plan to authorize, modify, or deny care for persons with similar illness or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under your contract. These Policies are subject to change as new information becomes available. APPENDIX to General Approach to Evaluating the Utility of Genetic Panels Policy Prior Authorization Requirements This service (or procedure) is considered medically necessary in certain instances and investigational in others (refer to policy for details). For instances when the indication is medically necessary, clinical evidence is required to determine medical necessity. For instances when the indication is investigational, you may submit additional information to the Prior Authorization Department. Within five days before the actual date of service, the Provider MUST confirm with Blue Shield of California / Blue Shield of California Life & Health Insurance Company (Blue Shield) that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an 3 of 28

4 authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions. Questions regarding the applicability of this policy should also be directed to the Prior Authorization Department. Please call or visit the Provider Portal Evidence Basis for the Policy Rationale The purpose of this policy is to provide a framework for evaluating the utility of genetic panels that use newer genetic testing methodologies. In providing a framework for evaluating genetic panels, this policy will not attempt to determine the clinical utility of genetic testing for specific disorders. For most situations, this will mean that at least one mutation in the panel has already been determined to have clinical utility and that clinical indications for testing are established. Once the clinical utility for at least one of the included mutations in the panel is established, then the focus is on whether the use of a panel is a reasonable alternative to individual tests. New genetic technology, such as next generation sequencing and chromosomal microarray, has led to the ability to examine many genes simultaneously (Choi et al., 2009). This is turn has resulted in a proliferation of genetic panels. Panels using next generation technology are currently available in the areas of cancer, cardiovascular disease, neurologic disease, and for reproductive testing (Bell et al., 2011; Foo et al., 2013; Lin et al., 2012). These panels are intuitively attractive to use in clinical care because they can analyze multiple genes more quickly and may lead to greater efficiency in the work-up of genetic disorders. It is also possible that newer technology can be performed more cheaply than direct sequencing, although this may not be true in all cases. On the other hand, the use of newer sequencing techniques will be associated with a higher error rate than direct sequencing (Raymond et al., 2010). This has the potential to lower the diagnostic accuracy of genetic testing, and this could impact the clinical validity of testing. Another potential pitfall is the easy availability of a multitude of genetic information, much of which has uncertain clinical consequences. The intended use for these panels is variable, for example, for the diagnosis of hereditary disorders, a clinical diagnosis may be already established, and genetic testing is performed to determine whether this is a hereditary condition, and/or to determine the specific mutation that is present. In other cases, there is a clinical syndrome (phenotype) with a broad number of potential diagnoses, and genetic testing is used to make a specific diagnosis. For cancer panels, there are also different intended uses. Some panels may be intended to determine whether a known cancer is part of a hereditary cancer syndrome. Other panels may include somatic mutations in a tumor biopsy specimen that may help identify a cancer type or subtype and/or help select best treatment. 4 of 28

5 There is no standardization to the makeup of genetic panels. Composition of the panels is variable, and different commercial products for the same condition may test a different set of genes. The make-up of the panels is determined by the specific lab that has developed the test. In addition, the composition of any individual panel is likely to change over time, as new mutations are discovered and added to the existing panels. Despite the variability in the intended use and composition of panels, there are a finite number of broad panel types that can be identified and categorized. Once categorization is done, specific criteria regarding the utility of the panel can then be developed for each category. One difficulty with this approach is that the distinction between the different categories, and the distinction between the intended uses of the panels, may not be a clear one. Some panels will have features or intended uses that overlap among the different categories. Types of Panels The majority of genetic panel tests are laboratory derived tests that are not subject to U.S. Food and Drug Administration (FDA) approval. Labs are subject to Clinical Laboratory Improvement Amendment (CLIA) regulations that monitor high-complexity testing. The following is a representative, but not exhaustive list of available panels that use next generation sequencing or chromosomal microarray technology with corresponding CPT codes if available. Any specific tests referenced in this Medical Policy or the Table below are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one test over another, and is not intended to represent a complete listing of all tests available. Laboratory Test Name CPT Codes Ambry Genetics (Aliso Viejo, CA) CancerNext x x x x x x x x x x x 1 Ambry Genetics BreastNext x x x x x 1 Ambry Genetics ColoNext x x x x x x x x x 1 Ambry Genetics OvaNext x x x x x x x x x x x x x x x x x x x x x x x x x x x x x 1 5 of 28

6 81228 x x x x x x x x 1 Ambry Genetics PancNext x x x x x x x x x 1 Ambry Genetics RenalNext x x x x x x x x x 1 Ambry Genetics PGLNext x x x x 2 Ambry Genetics Pan Cardio Panel x x x x 12 Ambry Genetics Ambry Genetics ARUP Laboratories (Salt Lake City, UT) ARUP Laboratories ARUP Laboratories ARUP Laboratories ARUP Laboratories X-linked Intellectual Disability (XLID Next Gen Panel ) Marfan, Aneurysm and Related Disorders Panel Mitochondrial Disorders Panel (mtdna and 108 Nuclear Genes) Sequencing and Deletion/Duplication Aortopathy Panel, Sequencing and Deletion/Duplication, 10 Genes Autism Panel Vascular Malformations Panel, Sequencing and Deletion/Duplication, 10 Genes Retinitis Pigmentosa/Leber Congenital Amaurosis Panel x x x x x x x x x x x x x x x x x x x x x 2 ARUP Laboratories Periodic Fever Syndromes Panel x x 2 Baylor College of Medicine Pyruvade Dehydrogenase Deficiency x 1 (Houston, TX) (PDH Complex) and Mitochondrial x 1 Respiratory Chain Complex V Deficiency x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x 61 6 of 28

7 Baylor College of Medicine Baylor College of Medicine Baylor College of Medicine Baylor College of Medicine Counsyl Genomics (San Francisco, CA) Emory Genetics Laboratory (Decatur, GA) Panel by Massively Parallel Sequencing Myopathy/Rhabdomyolysis Panel by Massively Parallel Sequencing Comprehensive mtdna Analysis by Massively Parallel Sequencing Low Bone Mass Panel by Massively Parallel Sequencing Glycogen Storage Disorders (GSD) Comprehensive Panel by Massively Parallel Sequencing Counsyl Panel x x x x x x x x x 14 Autism Spectrum Disorders x x x 1 Emory Genetics Laboratory Cardiomyopathy Panel x x 1 Emory Genetics Laboratory Ciliopathies Panel x x x 1 Emory Genetics Laboratory Congenital Disorders of Glycosylation Panel x x 1 Emory Genetics Laboratory Epilepsy and Seizure Disorders Panel x x x 1 Emory Genetics Laboratory Eye Disorders Panel x x 1 Emory Genetics Laboratory Neuromuscular Disorders Panel x x x 1 Emory Genetics Laboratory Noonan Syndrome and Related Disorders x 1 Panel Emory Genetics Laboratory Proportionate Short Stature/Small for Gestation Age Panel: Comprehensive x 2 Emory Genetics Laboratory X-linked Intellectual Disability Panel x x x 1 GoodStart Genetics GoodStart Select (Cambridge, MA) Mayo Clinic (Rochester, MN) Signature Genomics (Spokane, WA) Hereditary Colon Cancer Multi-Gene Panel x x x x x x 1 Signature Precision Panel Prenatal x x x x x x Genetic panels will be classified into three major categories: panels for genetic and hereditary conditions, cancer panels, and reproductive panels. Within these categories, sub-categories will be created according to the intended use of the panels. 7 of 28

8 Panels for Genetic or Hereditary Conditions Genetic or hereditary conditions are generally single-gene disorders, which are inherited in Mendelian fashion. They are defined by a characteristic phenotype, which may be characteristic of a specific disease, or which may represent a syndrome that encompasses multiple underlying diseases. The intended use of these panels may be for: Diagnosis (i.e., to define the underlying molecular genetic etiology of a given disease or syndrome) Risk assessment in asymptomatic individuals There are several variations of panels for use in diagnosis or risk assessment of genetic or hereditary conditions. For the purposes of this review, panels will be divided into the following types: Panels containing mutations associated with a single condition: They generally include all of the known pathologic mutations for a defined disease, and do not include mutations associated with other diseases. An example of such a panel would be one that includes pathologic mutations for hypertrophic cardiomyopathy and that doesn't include mutations associated with other cardiovascular disorders. These panels can be used for diagnostic or risk assessment purposes. Panels containing mutations associated with multiple related conditions: They include all of the known pathologic mutations for a defined disease, and also include mutations associated with other related disorders. An example of such a panel would be a pan cardiomyopathy panel that includes pathologic mutations for hypertrophic cardiomyopathy and other types of cardiomyopathy, such as dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. These panels can be used for diagnostic or risk assessment purposes. Panels containing mutations for clinical syndromes that are associated with multiple distinct conditions: These panels include mutations that are associated with multiple potential disease states that define a particular clinical syndrome. In general, a specific diagnosis cannot be made without genetic testing, and genetic testing can identify one among a number of underlying disease states that manifests as a clinical syndrome. An example of this type of panel is a panel for intellectual disability that includes mutations associated with many potential underlying disease states. These panels are used for diagnostic purposes. Cancer Panels Genetic panels for cancer can be of several types, and may test for either germline or somatic mutations. The intended purpose of these panels can be for: Risk assessment in asymptomatic individuals Directing targeted treatment based on specific somatic mutations There are variations of panels for use in risk assessment or for directing targeted treatment. For the purposes of this review, panels will be divided into the following types: 8 of 28

9 Panels containing multiple mutations indicating risk for a specific type of cancer or cancer syndrome (germline mutations): These panels contain multiple related mutations that indicate susceptibility to one or more cancers. They include germline mutations and will generally be used for risk assessment in asymptomatic individuals who are at risk for mutations based on family history or other clinical data. An example of this type of panel would be a panel testing for multiple BRCA1 and BRCA2 mutations associated with hereditary breast and ovarian cancer syndrome. Panels containing multiple mutations that are associated with a wide variety of cancer types (somatic mutations): These panels are generally used to direct treatment with drugs that target specific mutations. They test for somatic mutations from tissue samples of existing cancers. Many of these somatic mutations are found across a wide variety of solid tumors. An example of this type of panel is the CancerNext panel (Ambry Genetics, Aliso Viejo, CA) that tests for a broad number of somatic mutations that can direct treatment. Reproductive Panels Reproductive panels test for mutations that are associated with heritable conditions and are intended either for: Preconception testing of at-risk individuals Preconception screening Preimplantation testing Prenatal (in utero) testing Preconception testing usually tests for mutations that are autosomal recessive or X-linked, or in some cases, for autosomal dominant mutations with late clinical onset. Preconception tests can be performed on parents who are at risk for a mutation based on family history, or can be done as screening tests in parents who do not have a family history suggestive of a mutation. Prenatal testing refers to tests that are performed during a pregnancy. At the present time, prenatal testing for genetic mutations is performed on the fetus, using amniocentesis or chorionic villous sampling. Testing of maternal blood for chromosomal aneuploidy is currently available, and in the future it may be possible to test for fetal mutations using maternal blood. There are variations of panels for use in preconception or prenatal testing. For the purposes of this review, panels will be divided into the following types: Panels containing mutations associated with a single disorder: These panels are generally performed in at-risk individuals who have a family history of a heritable disorder. An example of this type of panel would be a cystic fibrosis gene panel that is intended for use in individuals with a family history of cystic fibrosis. Panels containing mutations associated with multiple disorders: These panels are generally performed as screening tests for parents who do not have a family history of a heritable disorder. They can also be used to evaluate individuals who have a family history of a heritable disorder. An example of this type of panel is the Signature Precision Panel - Prenatal. 9 of 28

10 General Criteria Used in Evaluating Genetic Panels The following is a list of all the criteria that can be applied to evaluating genetic panels, with an explanation of the way the criteria are to be defined and applied. Test is Performed in a Clinical Laboratory Improvement Amendment (CLIA)-Licensed Lab Testing is performed in a laboratory licensed under CLIA for high-complexity testing (Requires delivery of a reproducible set of called, quality filtered variants from the sequencing platform) These calculations should occur prior to variant annotation, filtering, and manual interpretation for patient diagnosis Analytic Validity of Panels Approaches that of Direct Sequencing The analytic validity for detecting individual mutations, compared to the gold standard of conventional direct Sanger sequencing, is reported ο Testing methods are clearly described, and the overall analytic validity for that type of testing is defined Any decrease in analytic sensitivity and specificity is not large enough to result in a clinically meaningful difference in diagnostic accuracy (clinical validity) Clinical Utility has been Established for at Least One Component of the Panel For each panel, there is at least one mutation included for which clinical utility has been established The patient meets the clinical indications for testing of that mutation Panel Testing Offers Substantial Advantages in Efficiency Compared to Sequential Analysis of Individual Genes The composition of the panel is sufficiently complex such that next generation sequencing, or chromosomal microarray, is expected to offer considerable advantages. Complexity of testing can be judged by: ο The number of genes tested ο The size of the genes tested ο The heterogeneity of the genes tested The Impact of Ancillary Information is Well-Defined If a panel contains both indicated mutations and non-indicated mutations, the probability that the results of non-indicated mutations impact the patients is considered, taking into account the following possibilities: ο The information may be ignored (no further impact) ο The information may result in further testing or changes in management Positive impact Negative impact 10 of 28

11 The probability is that the results of non-indicated tests cause a negative impact on the patient Decision Making Based on Genetic Results is Well-Defined Results of genetic test will lead to changes in diagnosis and/or treatment The potential changes in treatment are defined prior to testing and are in accordance with current standard of care Changes in diagnosis or management are associated with improvements in health outcomes For prenatal and preconception testing: ο Alterations in reproductive decision making are expected, depending on the results of testing Yield of Testing is Acceptable for the Target Population The number of individuals who are found to have a pathologic mutation, in relation to the total number of individuals tested, is reasonable given the underlying prevalence and severity of the disorder, and the specific population that is being tested ο It is not possible to set an absolute threshold for acceptable yield across different clinical situations. Some guidance can be given from clinical precedence as follows: For diagnosis of hereditary disorders, genetic testing is generally performed when signs and symptoms of disease are present, including family history. The likelihood of a positive genetic test depends on the accuracy of the signs and symptoms (pre-test probability of disorder), and the clinical sensitivity of genetic testing. For disorders such as testing for congenital long QT syndrome and Duchenne's muscular dystrophy, the likelihood of a positive result in patients with signs and symptoms of disease is greater than 10%. ο For cancer susceptibility, testing is recommended for genetic abnormalities such as BRCA and Lynch syndrome when the likelihood of a positive result is in the range of 2-10% ο For a clinical syndrome that has multiple underlying etiologies, such as developmental delay in children, chromosomal microarray testing is recommended when the likelihood of a positive result is in the 5-20% range There is increase in yield over alternate methods of diagnosis, and this increase is clinically significant Other Issues to Consider Most tests will not, and possibly should not, be ordered by generalists ο Guidance for providers is appropriate on the expertise necessary to ensure that test ordering is done in optimal fashion 11 of 28

12 Many tests, particularly those for inherited disorders, should be accompanied by patient counseling, preferably by certified genetic counselors ο Counseling may be needed both before and after testing, depending on the specific condition being tested Criteria for Evaluating Utility of Panels for Hereditary or Genetic Conditions Clinical utility has been established for at least one component of the panel Test is performed in a CLIA-approved lab Analytic validity of panel approaches that of direct sequencing Panel offers substantial advantages (efficiency of work-up, cost) over sequential analysis of individual genes Is the intended use of the panel diagnostic or risk assessment? Diagnostic ο Diagnosis of heritable conditions and either of the following: Risk Assessment Hereditary basis of clinically defined disorder and either of the following: ο Panel includes mutations for disorder in question (e.g., Retinitis Pigmentosa Panel; Leigh Disease Panel) ο Panel includes mutations for disorder in question plus other disorders (e.g., Retinitis Pigmentosa/Leber Congenital Amaurosis Panel; Pan Cardio Panel; Noonan Syndrome and Related Disorders Panel) and the impact of ancillary information is well-defined Genetic etiology of a syndrome for which clinical diagnosis is not possible: ο Panels with multiple mutations associated with a clinical syndrome (e.g., X-linked Intellectual Disability Panel; Marfan, Aneurysm and Related Disorders Panel; Epilepsy Panel) and both of the following: The impact of ancillary information is well-defined Yield of testing is acceptable for the target population ο Risk assessment for asymptomatic individuals Testing for multiple mutations when there is no known mutation in family ο Panels with multiple mutations for a single condition (e.g., most panels for hereditary conditions can be used for this purpose when there is not a known mutation in the family) and yield of testing is acceptable for the target population Criteria for Evaluating Utility of Cancer Panels Clinical utility has been established for at least one component of the panel Test is performed in a CLIA-approved lab 12 of 28

13 Analytic validity of panel approaches that of direct sequencing Panel offers substantial advantages (efficiency of work-up, cost) over sequential analysis of individual genes Is the intended use of the panel risk assessment or targeted treatment by mutation analysis? Risk Assessment ο Risk assessment for asymptomatic individuals Testing for multiple mutations when there is no known mutation in family ο Panels with multiple mutations for a single type of cancer (e.g., Hereditary Colon Cancer Multi-Gene Panel; BreastNext Panel) and yield of testing is acceptable for the target population Targeted Treatment by Mutation Analysis ο Targeted treatment by mutation analysis and either of the following: Effective targeted treatment based on mutation analysis is available and either of the following: ο Panels with multiple mutations intended to direct treatment (all indicated tests) and yield of testing is acceptable for the target population ο Panels with multiple mutations intended to direct treatment (indicated plus non-indicated tests) (e.g., CancerNext panels, when there is an effective targeted treatment for the specific type of cancer) and the impact of ancillary information is well-defined Effective targeted treatment based on mutation analysis has not been established: ο Panels with multiple mutations intended to direct treatment (no indicated tests for that particular cancer) and all of the following: Decision making based on potential results is defined Yield of testing is acceptable for the target population The impact of ancillary information is well-defined Criteria for Evaluating Utility of Reproductive Panels Clinical utility has been established for at least one component of the panel Test is performed in a CLIA-approved lab Analytic validity of panel approaches that of direct sequencing Panel offers substantial advantages (efficiency of work-up, cost) over sequential analysis of individual genes Is the intended use of the panel preconception testing, prenatal testing, or preimplantation testing? Preconception Testing ο Preconception testing of at-risk individuals and either of the following: 13 of 28

14 Panels that include only mutations associated with increased risk (e.g., Ashkenazi Jewish Carrier test Panel; GoodStart Select Panel) and decision making based on genetic results is well-defined Panels that include mutations associated with increased risk plus other mutations (GoodStart Select Panel [full panel, not customized]) and both of the following: ο Decision making based on genetic results is well-defined ο Impact of ancillary information is well-defined ο Preconception screening in high-risk populations (e.g., Counsyl Panel) and both of the following: Yield of testing is acceptable for the target population Decision making based on genetic results is well-defined Prenatal Testing ο Prenatal testing and either of the following: Panels that include only mutations associated with increased risk (e.g., Signature Precision Panel Prenatal [customized]) and decision making based on genetic results is well-defined Panels that include mutations associated with increased risk plus other mutations (e.g., Signature Precision Panel Prenatal [full panel, not customized]) and both of the following: Preimplantation Testing Summary ο Yield of testing is acceptable for the target population ο Decision making based on genetic results is well-defined ο Preimplantation testing and either of the following: Panels that include only mutations associated with increased risk (e.g., Signature Precision Panel Prenatal [customized]) and decision making based on genetic results is well-defined Panels that include mutations associated with increased risk plus other mutations (e.g., Signature Precision Panel Prenatal [full panel, not customized]) and both of the following: ο Yield of testing is acceptable for the target population ο Decision making based on genetic results is well-defined Genetic panels using next generation technology or chromosomal microarray are available for many clinical conditions. The major advantage of these genetic panels is the ability to analyze many genes simultaneously, potentially improving the breadth and efficiency of genetic workup. Disadvantages of the panels are that their accuracy may be lower compared to direct sequencing and that the impact of a large amount of ancillary information is uncertain. 14 of 28

15 Panels can be classified into categories based on the intended use and composition of the panel. For each category of panels, specific criteria can be used to evaluate medical necessity. When all of the criteria for a given category of panels are met, that panel may be considered medically necessary. Benefit Application Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member. Some state or federal mandates (e.g., Federal Employee Program (FEP)) prohibit Plans from denying Food and Drug Administration (FDA) - approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone. This Policy relates only to the services or supplies described herein. Benefits may vary according to benefit design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Type Number Description CPT ASPA (aspartoacylase) (e.g., Canavan disease) gene analysis, common variants (e.g., E285A, Y231X) APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., Maple syrup urine disease) gene analysis, common variants (e.g., R183P, G278S, E422X) BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative 15 of 28

16 Type Number Description BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative BLM (Bloom syndrome, RecQ helicase-like) (e.g., Bloom syndrome) gene analysis, 2281del6ins7 variant BRAF (v-raf murine sarcoma viral oncogene homolog B1) (e.g., colon cancer), gene analysis, V600E variant BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (i.e., exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (i.e., exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; common variants (e.g., ACMG/ACOG guidelines) 16 of 28

17 Type Number Description CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; known familial variants CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; duplication/deletion variants CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; full gene sequence CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; intron 8 poly-t analysis (e.g., male infertility) CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *8, *17) CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN) CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *5, *6) Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g., Bacterial Artificial Chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis) Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities EGFR (epidermal growth factor receptor) (e.g., non-small cell lung cancer) gene analysis, common variants (e.g., exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q) F2 (prothrombin, coagulation factor II) (e.g., hereditary hypercoagulability) gene analysis, 20210G>A variant F5 (coagulation Factor V) (e.g., hereditary hypercoagulability) gene analysis, Leiden variant 17 of 28

18 Type Number Description FANCC (Fanconi anemia, complementation group C) (e.g., Fanconi anemia, type C) gene analysis, common variant (e.g., IVS4+4A>T) FMR1 (Fragile X mental retardation 1) (e.g., fragile X mental retardation) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles FMR1 (Fragile X mental retardation 1) (e.g., fragile X mental retardation) gene analysis; characterization of alleles (e.g., expanded size and methylation status) FLT3 (fms-related tyrosine kinase 3) (e.g., acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (i.e., exons 14, 15) G6PC (glucose-6-phosphatase, catalytic subunit) (e.g., Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (e.g., R83C, Q347X) GBA (glucosidase, beta, acid) (e.g., Gaucher disease) gene analysis, common variants (e.g., N370S, 84GG, L444P, IVS2+1G>A) GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (e.g., nonsyndromic hearing loss) gene analysis; full gene sequence GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (e.g., nonsyndromic hearing loss) gene analysis; known familial variants GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (e.g., nonsyndromic hearing loss) gene analysis, common variants (e.g., 309kb [del(gjb6-d13s1830)] and 232kb [del(gjb6-d13s1854)]) HEXA (hexosaminidase A [alpha polypeptide]) (e.g., Tay- Sachs disease) gene analysis, common variants (e.g., 1278insTATC, G>C, G269S) HFE (hemochromatosis) (e.g., hereditary hemochromatosis) gene analysis, common variants (e.g., C282Y, H63D) 18 of 28

19 Type Number Description HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g., Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, and Constant Spring) IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (e.g., familial dysautonomia) gene analysis, common variants (e.g., T>C, R696P) IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (e.g., polymerase chain reaction) IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (e.g., Southern blot) IGH@ (Immunoglobulin heavy chain locus) (e.g., leukemia and lymphoma, B-cell), variable region somatic mutation analysis IGK@ (Immunoglobulin kappa light chain locus) (e.g., leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (e.g., pretransplant recipient and donor germline testing, posttransplant non-hematopoietic recipient germline [e.g., buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells) Comparative analysis using Short Tandem Repeat (STR) markers; each additional specimen (e.g., additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (List separately in addition to code for primary procedure) 19 of 28

20 Type Number Description Chimerism (engraftment) analysis, post transplantation specimen (e.g., hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection Chimerism (engraftment) analysis, post transplantation specimen (e.g., hematopoietic stem cell), includes comparison to previously performed baseline analyses; with cell selection (e.g., CD3, CD33), each cell type JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) gene analysis, p.val617phe (V617F) variant KRAS (v-ki-ras2 Kirsten rat sarcoma viral oncogene) (e.g., carcinoma) gene analysis, variants in codons 12 and Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full sequence analysis Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); known familial sequence variant Long QT syndrome gene analyses (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); duplication/deletion variants MCOLN1 (mucolipin 1) (e.g., Mucolipidosis, type IV) gene analysis, common variants (e.g., IVS3-2A>G, del6.4kb) MTHFR (5,10-methylenetetrahydrofolate reductase) (e.g., hereditary hypercoagulability) gene analysis, common variants (e.g., 677T, 1298C) MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants MLH1 (mutl homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants 20 of 28

21 Type Number Description MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants MSH2 (muts homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants MSH6 (muts homolog 6 [E. coli]) (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis MSH6 (muts homolog 6 [E. coli]) (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants MSH6 (muts homolog 6 [E. coli]) (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants Microsatellite instability analysis (e.g., hereditary nonpolyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (e.g., BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, exon 12 variants PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; common breakpoints (e.g., intron 3 and intron 6), qualitative or quantitative 21 of 28

22 Type Number Description PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; single breakpoint (e.g., intron 3, intron 6 or exon 6), qualitative or quantitative PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie- Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie- Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie- Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (e.g., Niemann-Pick disease, Type A) gene analysis, common variants (e.g., R496L, L302P, fsp330) 22 of 28

23 Type Number Description SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (e.g., alpha-1- antitrypsin deficiency), gene analysis, common variants (e.g., *S and *Z) TRB@ (T cell antigen receptor, beta) (e.g., leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (e.g., polymerase chain reaction) TRB@ (T cell antigen receptor, beta) (e.g., leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (e.g., Southern blot) TRG@ (T cell antigen receptor, gamma) (e.g., leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s) UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (e.g., irinotecan metabolism), gene analysis, common variants (e.g., *28, *36, *37) VKORC1 (vitamin K epoxide reductase complex, subunit 1) (e.g., warfarin metabolism), gene analysis, common variants (e.g., -1639/3673) Molecular pathology procedure, Level 1(e.g., identification of single germline variant [e.g., SNP] by techniques such as restriction enzyme digestion or melt curve analysis) Molecular pathology procedure, Level 2 (e.g., 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) Molecular pathology procedure, Level 3 (e.g., >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) 23 of 28

24 Type Number Description Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) Molecular pathology procedure, Level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of exons) Molecular pathology procedure, Level 7 (e.g., analysis of exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of exons, cytogenomic array analysis for neoplasia) Molecular pathology procedure, Level 8 (e.g., analysis of exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) Molecular pathology procedure, Level 9 (e.g., analysis of >50 exons in a single gene by DNA sequence analysis) Aortic dysfunction or dilation (e.g., marfan syndrome, loeys dietz syndrome, ehler danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1 TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK Aortic dysfunction or dilation (e.g., marfan syndrome, loeys dietz syndrome, ehler danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1 24 of 28